化瘀明目合剂治疗非增殖性糖尿病视网膜病变的临床研究

目的 观察化瘀明目合剂对非增殖性糖尿病视网膜病变（non-proliferative diabetic retinopathy, NPDR）的疗效。方法 将35例（68眼）NPDR患者随机分为2组，予对照组16例（32眼）口服羟苯磺酸钙胶囊（昊畅），予治疗组19例（36眼）口服化瘀明目合剂。2组均治疗12周。治疗后比较两组中医证候、视力和眼底病变的疗效；治疗前后分别检测两组患者空腹血糖、糖化血红蛋白、血脂水平。结果 在改善NPDR患者的临床症状、眼底病变和提高视力方面，治疗组显著优于对照组（P<0.05）；治疗组患者治疗后血清总胆固醇、三酰甘油水平均较治疗前显著降低（P<0.05），高密度脂蛋白水平较治疗前显著升高（P<0.05）。两组治疗前后空腹血糖、糖化血红蛋白A1c和低密度脂蛋白水平均无显著变化。结论 化瘀明目合剂对NPDR有明显疗效。

Clinical Efficacy of Huayu Mingmu Mixture in Treatment of Non-proliferative Diabetic Retinopathy

Objective To study the clinical efficacy of Huayu Mingmu Mixture (for expelling blood stasis and improving eyesight) in the treatment of non-proliferative diabetic retinopathy (NPDR).Methods Thirty-five patients with NPDR (68 eyes) were randomly divided into control group (16 cases, 32 eyes) and treatment group (19 cases, 36 eyes). The control group was orally given calcium dobesilate capsules (Hao Chang), while the treatment group was orally given Huayu Mingmu Mixture. The course of treatment was 12 weeks for both groups. After treatment, the two groups were compared in terms of the improvements in traditional Chinese medicine syndrome, eyesight, and fundus lesions. In addition, the changes in fasting blood glucose, glycosylated hemoglobin, and blood lipids were assessed. Results After treatment, the treatment group had significantly more improvements in clinical symptoms, fundus lesions, and eyesight than the control group (P<0.05); the treatment group showed significant decreases in serum levels of total cholesterol and triglyceride (P<0.05) and a significant increase in high-density lipoprotein level (P<0.05). Neither group showed significant changes in fasting blood glucose, hemoglobin A1c, and low-density lipoprotein after treatment. Conclusion Huayu Mingmu Mixture has significant efficacy in the treatment of NPDR.